

Special Issue

Clinical Application of Proton Pencil Beam Scanning Radiotherapy in Cancer

Message from the Guest Editor

Proton radiotherapy (PRT) has rapidly evolved as a method of radiation therapy within the last 15 years. The availability of PRT keeps increasing, the number of centers has more than doubled, and PRT has spread to almost all continents. PBS IMPT, which offers clinical benefits, is currently widely employed for a variety of diagnoses, and various clinical trials are ongoing. Finally, consistent data collection and evaluation of trials results may reveal the benefit of PBS IMPT. The number of publications on PBS IMPT keeps increasing together with the increasing availability of the technology. The summarized and rigorously analysed data, ready for publication, justifies the use of PBS IMPT in particular contexts.

Guest Editor

Dr. Pavel Vitek
Proton Therapy Center Czech, 180 00 Prague, Czech Republic

Deadline for manuscript submissions

31 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/234602

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)